Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01083667 · ClinicalTrials.gov registry record · Phase 1
SOD1 Inhibition by Pyrimethamine in Familial Amyotrophic Lateral Sclerosis (ALS)
A Phase 1 study, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT01083667 is a Phase 1 study that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 32 participants.
The verdict
NCT01083667, a Phase 1 study, has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
The objective of this study will be to evaluate the safety, tolerability and effect on SOD1 levels by pyrimethamine in patients with familial amyotrophic lateral sclerosis.
Interventions
- DRUG Pyrimethamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2009-11 |
| Est. Completion | 2016-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01083667
The ClinicalTrials.gov registry entry for NCT01083667 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pyrimethamine is the first listed.
NCT01083667 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01083667 about?
NCT01083667 is a clinical study titled "SOD1 Inhibition by Pyrimethamine in Familial Amyotrophic Lateral Sclerosis (ALS)". The objective of this study will be to evaluate the safety, tolerability and effect on SOD1 levels by pyrimethamine in patients with familial amyotrophic lateral sclerosis.
What is the current status of trial NCT01083667?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2009-11. Estimated completion is 2016-05.
What interventions are being tested in trial NCT01083667?
The interventions under investigation include: Pyrimethamine (DRUG).
Who is sponsoring clinical trial NCT01083667?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.